Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06396585
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-04-30
Brief Title:
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
Sponsor:
Fujian Cancer Hospital
Organization:
Fujian Cancer Hospital
Organization Data
Organization:
Fujian Cancer Hospital
Class:
OTHER_GOV
Study ID:
TASTE Trial
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fujian Cancer Hospital
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None